Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy
Identifieur interne : 004A30 ( Main/Curation ); précédent : 004A29; suivant : 004A31Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy
Auteurs : Chaodong Kastner [France] ; M. T. Herrero [France, Espagne] ; E. C. Hirsch [France] ; J. Guillen [Espagne] ; M. R. Luquin [Espagne] ; F. Javoy-Agid [France] ; J. A. Obeso [Espagne] ; Yves Agid [France]Source :
- Annals of Neurology [ 0364-5134 ] ; 1994-08.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Dopamine (analysis), G(M1) Ganglioside (therapeutic use), Levodopa (therapeutic use), Macaca fascicularis, Neurons (chemistry), Neurons (pathology), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Parkinson Disease, Secondary (enzymology), Parkinson Disease, Secondary (pathology), Tyrosine 3-Monooxygenase (metabolism).
- MESH :
- chemical , analysis : Dopamine.
- chemical , metabolism : Tyrosine 3-Monooxygenase.
- chemical , therapeutic use : G(M1) Ganglioside, Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- chemistry : Neurons.
- drug therapy : Parkinson Disease, Secondary.
- enzymology : Parkinson Disease, Secondary.
- pathology : Neurons, Parkinson Disease, Secondary.
- Animals, Macaca fascicularis.
Abstract
Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, using a semiquantitative immunocytochemical method. Thirteen monkeys were rendered parkinsonian by weekly intravenous injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) for 2 (subacute treatment) or 20 (chronic treatment) weeks. Three of the monkeys received levodopa and 3 others received GM1 ganglioside. The loss of dopaminergic neurons in the mesencephalon of the MPTP‐intoxicated monkeys was severe in the substantia nigra, intermediate in cell groups A8 and A10, and almost undetectable in the central gray substance. After both subacute and chronic treatment, the cellular content of tyrosine hydroxylase was reduced by 40% in the surviving neurons of the lesioned substantia nigra, but by less in the other mesencephalic dopaminergic regions. Neuronal survival and tyrosine hydroxylase content in monkeys that had received levodopa were not significantly different. The cellular content of tyrosine hydroxylase was increased in the substantia nigra of the monkeys that received GM1 ganglioside injections. The results show that the decreased expression of tyrosine hydroxylase found in nigral dopaminergic neurons after partial degeneration of the mesostriatal dopaminergic system is not influenced by levodopa treatment and is partially reversed by GM1 ganglioside administration.
Url:
DOI: 10.1002/ana.410360213
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E80
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001E78
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001A80
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001668
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001627
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001627
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001D00
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001D00
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001D00
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005384
Links to Exploration step
ISTEX:0054A336EE537968F5CE09F452C10BBA0BC1A4D9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy</title><author><name sortKey="Kastner, Chaodong" sort="Kastner, Chaodong" uniqKey="Kastner C" first="Chaodong" last="Kastner">Chaodong Kastner</name></author><author><name sortKey="Herrero, M T" sort="Herrero, M T" uniqKey="Herrero M" first="M. T." last="Herrero">M. T. Herrero</name></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name></author><author><name sortKey="Guillen, J" sort="Guillen, J" uniqKey="Guillen J" first="J." last="Guillen">J. Guillen</name></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name></author><author><name sortKey="Javoy Gid, F" sort="Javoy Gid, F" uniqKey="Javoy Gid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name></author><author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J. A." last="Obeso">J. A. Obeso</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0054A336EE537968F5CE09F452C10BBA0BC1A4D9</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/ana.410360213</idno><idno type="url">https://api.istex.fr/document/0054A336EE537968F5CE09F452C10BBA0BC1A4D9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E80</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E80</idno><idno type="wicri:Area/Istex/Curation">001E78</idno><idno type="wicri:Area/Istex/Checkpoint">001A80</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A80</idno><idno type="wicri:doubleKey">0364-5134:1994:Kastner C:decreased:tyrosine:hydroxylase</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7914399</idno><idno type="wicri:Area/PubMed/Corpus">001668</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001668</idno><idno type="wicri:Area/PubMed/Curation">001627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001627</idno><idno type="wicri:Area/PubMed/Checkpoint">001627</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001627</idno><idno type="wicri:Area/Ncbi/Merge">001D00</idno><idno type="wicri:Area/Ncbi/Curation">001D00</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D00</idno><idno type="wicri:doubleKey">0364-5134:1994:Kastner A:decreased:tyrosine:hydroxylase</idno><idno type="wicri:Area/Main/Merge">005384</idno><idno type="wicri:Area/Main/Curation">004A30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy</title><author><name sortKey="Kastner, Chaodong" sort="Kastner, Chaodong" uniqKey="Kastner C" first="Chaodong" last="Kastner">Chaodong Kastner</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, 47 Bd de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Herrero, M T" sort="Herrero, M T" uniqKey="Herrero M" first="M. T." last="Herrero">M. T. Herrero</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology and Experimental Neurology, CIFA, University of Navarre, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Guillen, J" sort="Guillen, J" uniqKey="Guillen J" first="J." last="Guillen">J. Guillen</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology and Experimental Neurology, CIFA, University of Navarre, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology and Experimental Neurology, CIFA, University of Navarre, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Javoy Gid, F" sort="Javoy Gid, F" uniqKey="Javoy Gid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J. A." last="Obeso">J. A. Obeso</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology and Experimental Neurology, CIFA, University of Navarre, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994-08">1994-08</date><biblScope unit="volume">36</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="206">206</biblScope><biblScope unit="page" to="214">214</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">0054A336EE537968F5CE09F452C10BBA0BC1A4D9</idno><idno type="DOI">10.1002/ana.410360213</idno><idno type="ArticleID">ANA410360213</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Dopamine (analysis)</term><term>G(M1) Ganglioside (therapeutic use)</term><term>Levodopa (therapeutic use)</term><term>Macaca fascicularis</term><term>Neurons (chemistry)</term><term>Neurons (pathology)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Parkinson Disease, Secondary (enzymology)</term><term>Parkinson Disease, Secondary (pathology)</term><term>Tyrosine 3-Monooxygenase (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>G(M1) Ganglioside</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neurons</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Macaca fascicularis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, using a semiquantitative immunocytochemical method. Thirteen monkeys were rendered parkinsonian by weekly intravenous injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) for 2 (subacute treatment) or 20 (chronic treatment) weeks. Three of the monkeys received levodopa and 3 others received GM1 ganglioside. The loss of dopaminergic neurons in the mesencephalon of the MPTP‐intoxicated monkeys was severe in the substantia nigra, intermediate in cell groups A8 and A10, and almost undetectable in the central gray substance. After both subacute and chronic treatment, the cellular content of tyrosine hydroxylase was reduced by 40% in the surviving neurons of the lesioned substantia nigra, but by less in the other mesencephalic dopaminergic regions. Neuronal survival and tyrosine hydroxylase content in monkeys that had received levodopa were not significantly different. The cellular content of tyrosine hydroxylase was increased in the substantia nigra of the monkeys that received GM1 ganglioside injections. The results show that the decreased expression of tyrosine hydroxylase found in nigral dopaminergic neurons after partial degeneration of the mesostriatal dopaminergic system is not influenced by levodopa treatment and is partially reversed by GM1 ganglioside administration.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004A30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:0054A336EE537968F5CE09F452C10BBA0BC1A4D9
|texte= Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy
}}
| This area was generated with Dilib version V0.6.29. |  |